The Best Dividend in Big Pharma: Sanofi SA (SNY), Pfizer Inc. (PFE), GlaxoSmithKline plc (GSK)

Page 1 of 2

Big pharma’s a good place to start if you’re looking for dividend stocks. Many of the largest players in the industry sport top dividends, rewarding long-term investors for their patience and faith. Separating the best big pharma stocks from the laggards can be a tricky affair given all of the drugs, businesses, and products that one major pharmaceutical company alone can offer. It’s even trickier when you’re on the lookout for income-paying stocks for the long run, given the patent cliff’s toll on big pharma and the recent spate of companies spinning off unwanted businesses.

However, a quick glance across the Atlantic reveals one steady company with its eyes on the future, a stock that income investors everywhere should love: Sanofi SA (NYSE:SNY).

Sanofi SA (ADR) (NYSE:SNY)Why Sanofi?
This French pharmaceutical giant might not be your first thought when you think of big pharma’s titans, but make no mistake: This company’s in pole position for the long haul.

Sanofi’s taken a hit lately from the patent expiration of Plavix, the company’s once-flagship blood clot drug that has since been torn down by generic competition. The drug’s still one of Sanofi’s top sellers with more than $600 million in sales in the most recent quarter, but it lost more than 6% in revenue on a constant currency basis.

Income investing is for the long term, however, and Sanofi’s got more than enough in its cabinet of drugs to fuel the future despite Plavix’s hits. Insulin medication Lantus will power Sanofi through 2015, when its patent expires; the drug is the company’s top seller, recording more than  $1.7 billion in the last quarter alone, and sales are growing at a steady double-digit clip. Although Sanofi still expects profits to fall by as much as 5% in 2013 because of generic competition — an expectation that sent shares plunging when announced — the company’s pipeline and recent moves should ease an income investor’s concern over the future.

The company’s acquisition of Genzyme back in 2011 has turned out to be a great move. With the approval of multiple sclerosis drug Aubagio last year and new rare disease treatment Kynamro fresh off its own approval, Sanofi’s riding a wave of regulatory victories. These drugs and more should help the company deal with future patent expirations such as Lantus; it’s a key factor that distinguishes Sanofi’s stability over more risky competitors like AbbVie Inc (NYSE:ABBV), which relies on one drug — Humira — to power more than half of its sales and could be crippled by its patent loss.

But are future drug sales and relief from the patent cliff Sanofi’s only distinguishing features over other big pharma dividend players? Hardly.

Separating from the pack
Sanofi might not offer the highest dividend in big pharma; its 3.6% yield only equals that of big-name rival Pfizer Inc. (NYSE:PFE), and fellow pharmaceutical giant GlaxoSmithKline plc (NYSE:GSK) offers a superior 5.1% yield. That’s a tempting pick for dividend investors on a purely financial basis.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

The 10 Biggest Outlet Malls in USA

The 5 Most Popular Rap Songs of All Time

The 10 Countries that Eat the Most Meat

The10 Most Expensive Countries to Fly To

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!